drugset / Trial / NCT06863987

A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents

NCT06863987

Phase 3 Enrolling by invitation 342 enrolled Shandong New Time Pharmaceutical Co., LTD
NaParallel-groupDouble-blindTreatment

Summary

This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.

Timeline

Start
2025-02-05
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Valsartan Small molecule 40 mg Oral
Subject Valsartan Small molecule 80 mg Oral